227 related articles for article (PubMed ID: 34814822)
1. Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials.
Gozzetti A; Bocchia M
Rev Recent Clin Trials; 2022; 17(1):9-10. PubMed ID: 34814822
[TBL] [Abstract][Full Text] [Related]
2. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
3. Measurable Residual Disease and Decision-Making in Multiple Myeloma.
Derman BA; Fonseca R
Hematol Oncol Clin North Am; 2024 Apr; 38(2):477-495. PubMed ID: 38184470
[TBL] [Abstract][Full Text] [Related]
4. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
Medina A; Puig N; Flores-Montero J; Jimenez C; Sarasquete ME; Garcia-Alvarez M; Prieto-Conde I; Chillon C; Alcoceba M; Gutierrez NC; Oriol A; Rosinol L; Bladè J; Gironella M; Hernandez MT; Gonzalez-Calle V; Cedena MT; Paiva B; San-Miguel JF; Lahuerta JJ; Mateos MV; Martinez-Lopez J; Orfao A; Gonzalez M; Garcia-Sanz R
Blood Cancer J; 2020 Oct; 10(10):108. PubMed ID: 33127891
[TBL] [Abstract][Full Text] [Related]
5. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
Bal S; Costa LJ
Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
[TBL] [Abstract][Full Text] [Related]
6. Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry.
Ho C; Syed M; Roshal M; Petrova-Drus K; Moung C; Yao J; Quesada AE; Benhamida J; Vanderbilt C; Liu Y; Zhu M; Yu W; Maciag L; Wang M; Ma Y; Gao Q; Rustad EH; Hultcrantz M; Diamond BT; Zheng-Lin B; Huang Y; Hutt K; Miller JE; Dogan A; Nafa K; Landgren O; Arcila ME
J Mol Diagn; 2021 Feb; 23(2):181-199. PubMed ID: 33217553
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
[TBL] [Abstract][Full Text] [Related]
8. Long-term CR Multiple Myeloma Patients Show Cured or MGUS-like Minimal Residual Disease Pattern by Next Generation Flow.
Gozzetti A; Pacelli P; Raspadori D; Bestoso E; Tocci D; Sicuranza A; Bocchia M
Rev Recent Clin Trials; 2022; 17(2):92-96. PubMed ID: 35578845
[TBL] [Abstract][Full Text] [Related]
9. Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma.
Kim HY; Yoo IY; Lim DJ; Kim HJ; Kim SH; Yoon SE; Kim SJ; Cho D; Kim K
Ann Lab Med; 2022 Sep; 42(5):558-565. PubMed ID: 35470273
[TBL] [Abstract][Full Text] [Related]
10. Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma.
Foureau DM; Paul BA; Guo F; Lipford EH; Fesenkova K; Tjaden E; Drummond K; Bhutani M; Atrash S; Ndiaye A; Varga C; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e41-e50. PubMed ID: 36443182
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
12. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
[TBL] [Abstract][Full Text] [Related]
13. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease in multiple myeloma: Benefits of flow cytometry.
Galtseva IV; Davydova YO; Kapranov NM; Julhakyan HL; Mendeleeva LP
Int J Lab Hematol; 2018 Feb; 40(1):12-20. PubMed ID: 29058372
[TBL] [Abstract][Full Text] [Related]
15. Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma.
Bal S; Weaver A; Cornell RF; Costa LJ
Br J Haematol; 2019 Sep; 186(6):807-819. PubMed ID: 31364160
[TBL] [Abstract][Full Text] [Related]
16. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
[TBL] [Abstract][Full Text] [Related]
17. Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity.
Berger N; Kim-Schulze S; Parekh S
Adv Exp Med Biol; 2018; 1100():141-159. PubMed ID: 30411265
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic value of minimal residual disease detection in multiple myeloma].
Takamatsu H
Nihon Rinsho; 2015 Jan; 73(1):69-73. PubMed ID: 25626307
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.
Maclachlan KH; Came N; Diamond B; Roshal M; Ho C; Thoren K; Mayerhoefer ME; Landgren O; Harrison S
Pathology; 2021 Apr; 53(3):385-399. PubMed ID: 33674146
[TBL] [Abstract][Full Text] [Related]
20. Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators.
Van der Straeten J; De Brouwer W; Kabongo E; Dresse MF; Fostier K; Schots R; Van Riet I; Bakkus M
J Mol Diagn; 2021 May; 23(5):599-611. PubMed ID: 33549860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
